Nisa Investment Advisors
AKRO

Nisa Investment Advisors’s Akero Therapeutics AKRO Stock Holding History

Nisa Investment Advisors’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,391
Closed -$114K – 2966
2025
Q3 		$114K Hold
2,391
– – ﹤0.01% 1396
2025
Q2 		$128K Buy
2,391
+1,429
+149% +$64.9K ﹤0.01% 1322
2025
Q1 		$38.9K Buy
962
+2
+0.2% +$85 ﹤0.01% 1664
2024
Q4 		$26.7K Buy
960
+174
+22% +$5.27K ﹤0.01% 1851
2024
Q3 		$22.6K Buy
786
+24
+3% +$626 ﹤0.01% 1878
2024
Q2 		$17.9K Buy
762
+372
+95% +$7.96K ﹤0.01% 1986
2024
Q1 		$9.85K Buy
390
+70
+22% +$1.68K ﹤0.01% 2036
2023
Q4 		$7.47K Sell
320
-660
-67% -$13K ﹤0.01% 2078
2023
Q3 		$49.6K Buy
980
+300
+44% +$14K ﹤0.01% 1729
2023
Q2 		$31.7K Buy
680
+179
+36% +$8.2K ﹤0.01% 1916
2023
Q1 		$19K Sell
501
-102,520
-100% -$4.57M ﹤0.01% 2019
2022
Q4 		$5.65M Buy
103,021
+103,000
+490,476% +$4.41M 0.04% 392
2022
Q3 		$1K Buy
+21
New +$321 ﹤0.01% 2384

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Nisa Investment Advisors's AKRO Position: Q4 2025 in Review

Nisa Investment Advisors sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 2,391 shares — an estimated $114K sold.

Nisa Investment Advisors first reported a position in AKRO in Q3 2022 and held it in 13 quarters. The position peaked at $5.65M in Q4 2022. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Nisa Investment Advisors reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Nisa Investment Advisors sold 2,391 Akero Therapeutics shares in Q4 2025, an estimated $114K.
  • Nisa Investment Advisors first reported a position in Akero Therapeutics in Q3 2022 and held it in 13 quarters.
  • Nisa Investment Advisors's Akero Therapeutics position peaked at $5.65M in Q4 2022.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Nisa Investment Advisors's 13F filing for Q4 2025, filed 15 Jan 2026.